IDH2 and acute myeloid leukemia: IDH2 inhibition in clinical trials. Both monotherapy with enasidenib and combination therapy with enasidenib and 5-azacytidine vs. 5-azacytidine alone showed high response rates in IDH2 mutant AML patients [158,173,174,175].